# 9. Monitoring Parameters

[← Previous: Dosing Guidelines](08-dosing-guidelines.md) | [Back to Main](../README.md) | [Next: Treatment Algorithm →](10-treatment-algorithm.md)

---

## 9.1 Baseline Evaluations (Before Starting Any ASM)

| Test | Rationale |
|------|-----------|
| CBC with differential | Baseline for bone marrow suppression monitoring |
| Comprehensive metabolic panel | Renal/hepatic function baseline |
| LFTs | Hepatotoxicity risk assessment |
| EKG | Cardiac conduction (especially for lacosamide, carbamazepine) |
| Pregnancy test | Women of childbearing potential |
| HLA-B*15:02 | Asian ancestry before CBZ/OXC/PHT |

---

## 9.2 ASM-Specific Monitoring

| ASM | Parameter | Frequency |
|-----|-----------|-----------|
| **Valproate** | LFTs, CBC, ammonia | Every 3-6 months |
| **Carbamazepine** | CBC, LFTs, sodium | Every 3-6 months |
| **Oxcarbazepine** | Sodium | Every 3-6 months; more often if symptomatic |
| **Phenytoin** | Drug level, CBC, vitamin D, bone density | Annually; levels as needed |
| **Lacosamide** | EKG | Baseline, after titration |
| **Felbamate** | CBC, LFTs | Every 2 weeks for 1 year, then quarterly |
| **Vigabatrin** | Visual fields | Baseline, every 3 months |
| **Topiramate** | Bicarbonate, renal function | Every 6-12 months |

---

## 9.3 Monitoring Schedule Summary

### First 3 Months (Initiation Phase)

| Week | Monitoring |
|------|------------|
| **Baseline** | CBC, CMP, LFTs, pregnancy test, EKG (if indicated) |
| **Week 2** | Clinical assessment, tolerability |
| **Week 4** | Repeat labs if on valproate, carbamazepine |
| **Week 8** | Clinical assessment, dose optimization |
| **Week 12** | Labs (ASM-specific), clinical assessment |

### Maintenance Phase (Stable on Therapy)

| Frequency | Monitoring |
|-----------|------------|
| **Every 3-6 months** | Clinical assessment, seizure diary review |
| **Every 6-12 months** | ASM-specific labs |
| **Annually** | Comprehensive labs, bone health (if on enzyme inducers) |

---

## 9.4 Pregnancy Monitoring

| Parameter | Frequency |
|-----------|-----------|
| ASM levels (especially lamotrigine) | Monthly during pregnancy, postpartum week 1-2 |
| Fetal ultrasound | 11-14 weeks (NT), 18-22 weeks (anatomy), 28-32 weeks (growth) |
| Alpha-fetoprotein | If on valproate or carbamazepine |
| Folic acid supplementation | Pre-conception through first trimester (4-5 mg/day) |

### Lamotrigine Level Monitoring in Pregnancy

```
Pre-conception → Establish baseline level
Each trimester → Monthly levels
├── If level drops >25% → Consider dose increase
├── If level drops >50% → Increase dose
└── Postpartum → Levels return to baseline; reduce dose
```

---

## 9.5 Drug Level Interpretation

### Phenytoin

| Situation | Total Level | Free Level | Action |
|-----------|-------------|------------|--------|
| Therapeutic | 10-20 mcg/mL | 1-2 mcg/mL | Continue current dose |
| Subtherapeutic | <10 mcg/mL | <1 mcg/mL | Increase dose |
| Toxic | >20 mcg/mL | >2 mcg/mL | Hold/reduce dose |
| Renal failure | May be low | Use free level | Adjust based on free level |
| Hypoalbuminemia | May be low | Use free level | Adjust based on free level |

### Valproate

| Level | Interpretation |
|-------|----------------|
| <50 mcg/mL | Subtherapeutic; consider dose increase |
| 50-100 mcg/mL | Therapeutic range |
| 100-150 mcg/mL | High therapeutic; monitor for toxicity |
| >150 mcg/mL | Toxic; reduce dose |

---

## 9.6 When to Check Drug Levels

### Routine Indications

- Baseline after reaching maintenance dose
- After dose changes (allow 5 half-lives for steady state)
- Suspected toxicity
- Breakthrough seizures
- Medication adherence concerns

### Special Situations

| Situation | Timing |
|-----------|--------|
| **Pregnancy** | Each trimester + postpartum |
| **Drug interactions** | 1-2 weeks after adding/removing interacting drug |
| **Renal impairment** | More frequent; after any renal function change |
| **Hepatic impairment** | Free levels for protein-bound drugs |
| **Status epilepticus** | During acute management |

---

## 9.7 Red Flags Requiring Immediate Evaluation

### Clinical

- New rash (especially with fever or mucosal involvement)
- Significant behavior change or suicidality
- New cognitive decline
- Unexplained bruising or bleeding
- Severe abdominal pain
- Jaundice

### Laboratory

| Finding | Possible Cause | Action |
|---------|----------------|--------|
| WBC <3000 or ANC <1500 | Bone marrow suppression | Hold ASM; urgent evaluation |
| Platelets <100,000 | Valproate-associated | Consider dose reduction or switch |
| ALT/AST >3x ULN | Hepatotoxicity | Hold ASM; urgent evaluation |
| Ammonia elevated + altered mental status | Valproate encephalopathy | Hold valproate; urgent evaluation |
| Sodium <125 mEq/L | OXC/CBZ-associated SIADH | Discontinue offending ASM |

---

## 9.8 Bone Health Monitoring

### For Patients on Enzyme-Inducing ASMs

| Test | Timing | Target |
|------|--------|--------|
| Vitamin D (25-OH) | Baseline, annually | >30 ng/mL |
| Calcium | Annually | Normal range |
| DEXA scan | Baseline if risk factors; repeat per guidelines | T-score >-2.5 |

### Supplementation Recommendations

| Supplement | Dose |
|------------|------|
| Calcium | 1000-1200 mg/day |
| Vitamin D | 800-2000 IU/day (higher if deficient) |

---

## 9.9 Visual Field Monitoring (Vigabatrin)

```
BASELINE
├── Automated perimetry (Humphrey or Octopus)
└── Document baseline visual acuity

ONGOING (Every 3 months)
├── Repeat automated perimetry
├── Compare to baseline
└── Watch for peripheral field constriction

IF DEFECTS DETECTED
├── Consider vigabatrin discontinuation
├── Defects are typically irreversible
└── Weigh risk vs benefit (especially in infantile spasms)
```

---

[← Previous: Dosing Guidelines](08-dosing-guidelines.md) | [Back to Main](../README.md) | [Next: Treatment Algorithm →](10-treatment-algorithm.md)
